CBC vs CBD

CBC: Identity Established; receptor activity in the lab Demonstrated · in vitro (De Petrocellis 2011); benefits in people No primary evidence / catalogue in progress
CBD: Identity Established; one approved prescription medicine Established · regulatory fact; benefit claims for consumer products Low / catalogue in progress

From the evidence status row of the table below.

CBC sells on CBD's coat-tails, and on paper the ride looks earned. The two share one molecular formula, C21H30O2, arranged as two different structural isomers; both are non-intoxicating; and the plant builds both from CBGA. The resemblance ends at the evidence. CBD is the active ingredient in an approved prescription medicine and has been studied far more, while CBC's effects in people remain largely uncharacterised.

Whose claims are whose. Chemical identity, non-intoxicating status, biosynthesis and laboratory (in-vitro) pharmacology are verified and graded. Talk of effects, benefits or uses (mood, inflammation, pain, "entourage") is a claim made by third parties such as manufacturers, media or preliminary research, and CBG Atlas does not make, adopt or affirm it. Not medical or legal advice. The full disclaimer sits at the foot of this page.

At a glance

The top rows read like a tie. Drop to the bottom two and the gap opens up: CBD is heavily studied and regulated as a medicine ingredient, while CBC has barely been studied in people.

	CBC	CBD
Full name	CBCCannabichromene	CBDCannabidiol
Formula / CAS	CBCC21H30O2 / 20675-51-8	CBDC21H30O2 / 13956-29-1
Intoxicating?	CBCNo Established	CBDNo Established
General legal status	CBCHemp-derived CBC (≤0.3% Δ9-THC) is broadly legal federally in the US under the 2018 Farm Bill; rules vary by state and product class; not an FDA-approved food/supplement. Not legal advice.	CBDFalls under the same hemp framework (≤0.3% Δ9-THC) and varies by state; consumer CBD is not an FDA-approved food/supplement, although one prescription CBD medicine holds its own approval. Not legal advice.
Commonly marketed for (attributed — not our claim)	CBCMarketed next to CBD for mood, inflammation and skin; not established in humans	CBDMarketed for calm, sleep, stress and general wellness; not established for consumer products
Evidence status (graded)	CBCIdentity Established; receptor activity in the lab Demonstrated · in vitro (De Petrocellis 2011); benefits in people No primary evidence / catalogue in progress	CBDIdentity Established; one approved prescription medicine Established · regulatory fact; benefit claims for consumer products Low / catalogue in progress

Figure P · targets side by side

CBC and CBD at six targets: what our registry records, and where it records nothing

How to read a cell: An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
CB1 cannabinoid receptor: CBC: no graded interaction in our registry. CBD: damps activation (negative allosteric modulator; drawn as two bars), in vitro grade: Demonstrated study type: In vitro Laprairie 2015.
CB2 cannabinoid receptor: CBC: no graded interaction in our registry. CBD: blocks what activates it (antagonist of CB1/CB2 agonists), in a review, no rung of its own study type: Review Pertwee 2008.
α2-adrenoceptor: CBC: no graded interaction in our registry. CBD: no graded interaction in our registry.
5-HT1A serotonin receptor: CBC: no graded interaction in our registry. CBD: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Russo 2005.
TRPV1 and TRPV2 ion channels: CBC: no graded interaction in our registry. CBD: no graded interaction in our registry.
TRPM8 ion channel: CBC: no graded interaction in our registry. CBD: no graded interaction in our registry.

An oxblood frame is a registry record measured in receptors, cells or tissue, which is what in vitro means, with the direction as a glyph: a bar blocks, a chevron activates, a chevron with a bar activates and then desensitises, two bars damp activation. A gold frame is a direction the registry holds only through a review, quoted with the qualification the source itself attaches; it carries no rung of its own. A dashed frame means the registry holds no graded interaction there, which is not the same as evidence of none. None of this is an effect in people, and none of it is a dose. CBC has no receptor-level record in our registry at any of the six targets: the registry is CBG-centred, and the empty column says so. Sources: Laprairie 2015, Pertwee 2008, Russo 2005. CBG's record at researcher depth is on the monograph's target map; the receptors themselves are drawn on the ECS map →

What the evidence supports

Strip out the marketing and the record sorts into three piles: settled chemistry for both, a little lab pharmacology for CBC, and one regulatory fact for CBD. Everything a shopper actually buys either compound for sits outside those piles, where benefits in people are mostly unproven.

Both are non-intoxicating, and both are structural isomers of C21H30O2. The atoms are the same and the arrangement differs, which makes the pair a neat lesson for anyone who assumes identical formulas mean identical effects. Established · chemical identity.
Both trace back to CBGA. The plant makes CBC through the CBCA branch and CBD through the CBDA branch, and heat decarboxylates each acid into its neutral form. Established · biosynthesis.
CBC has laboratory pharmacology on record. In lab studies it acts on the TRPA1 channel and inhibits the uptake of anandamide into cells (De Petrocellis 2011), mechanisms rather than proven benefits. Demonstrated · in vitro. It has also been reported to have antibacterial activity in vitro (Appendino 2008). Demonstrated · in vitro.
CBD's firmest point is a regulatory one. CBD is the active ingredient in a specific prescription medicine approved for certain rare seizure disorders. That medicine is a separate, regulated product, distinct from over-the-counter CBD, and its approval stays with it rather than lending weight to consumer benefit claims. Established · regulatory fact.
Neither has much human evidence as a consumer product. The mood, inflammation, pain and skin claims in marketing rest on preclinical (lab/animal) work at best, and controlled human trials have not established them, so a label making them for either compound is ahead of the data. No primary evidence (CBC) · Low (CBD) · catalogue in progress.
Our registry contains no head-to-head trial. No controlled human trial has compared the two on any outcome, which leaves a claim that one beats the other unsupported: an absence in the record, not a finding against either compound. No primary evidence · catalogue in progress.

Common questions

CBC vs CBD — what's the actual difference?

The main difference is how much is known about each, because the chemistry is almost the same. Both are non-intoxicating cannabinoids made from CBGA, and both have the formula C21H30O2, arranged as different structural isomers. Where they split is the library: CBD has a large research base and one approved prescription medicine, while CBC's effects in people are still largely uncharacterised.

Grade — Established (identity) · human comparison catalogue in progress

Do CBC and CBD get you high?

No. Both are non-intoxicating, and neither produces the high people associate with THC Established. THC intoxicates by activating the CB1 receptor, and neither compound is understood to work that way. The one wrinkle lives in the jar rather than the molecule: full-spectrum products of either compound can contain trace THC.

Grade — Established · non-intoxicating · trace-THC caveat

Which is more studied — CBC or CBD?

CBD, by a wide margin. It has a substantial research literature and is the active ingredient in an approved prescription medicine for certain rare seizure disorders, a regulated product distinct from consumer CBD Established · regulatory fact. CBC has barely reached controlled human trials, and its effects in people are catalogue in progress Low.

Grade — Established (CBD regulatory fact) · CBC human evidence not established

Which is better for inflammation or pain?

Nobody knows, because our registry holds no head-to-head human trial of the two No primary evidence. A claim that either is "better for inflammation" or "better for pain" has nothing to rest on. Both show related activity only in preclinical lab and animal work, not yet confirmed in people. CBD's bigger research file is tempting to read as a head start, but more studies of a compound are a measure of attention rather than evidence that it works better.

No primary evidence · no head-to-head human trial in our registry

Are CBC and CBD legal?

Generally yes, under the same US rules. Hemp-derived CBC and CBD at or below 0.3% Δ9-THC by dry weight are broadly treated as federally legal under the 2018 Farm Bill Established. The fine print belongs to the states and to product-class rules, which vary, and neither is an FDA-approved food or supplement. Check local law. (Not legal advice.)

Legal snapshot · dated and jurisdiction-specific · not legal advice; verify current local law

Will CBC or CBD show up on a drug test?

Standard drug tests look for THC and its metabolite (THC-COOH) rather than for CBC or CBD Established. The risk rides in with the trace THC that full- or broad-spectrum products of either compound can carry, which sometimes produces a positive result. The COA shows how much THC a batch contains. (Not medical advice.)

Grade — Established (tests target THC) · trace-THC caveat

Informational only — not our claims, and not advice

The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.

Verified sources: De Petrocellis 2011 (PMID 21175579; CBC acts on TRPA1 and inhibits anandamide uptake, in vitro) · Appendino 2008 (antibacterial, including against MRSA, in vitro). Every effect or benefit statement is either attributed to a third party or graded catalogue in progress.

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →

Keep exploring

The compounds compared

More comparisons

All comparisons

Reference